ROS1 INHIBITOR, A TARGETED DRUG FOR NON-SMALL CELL LUNG CANCER MARKET ANALYSIS BY TYPE, APPLICATION, REGIONS AND COMPANIES FORECAST
2024-11-27 | Pages: 200+ | Report ID: MD-R-2024-11-27-167730 | Others
Historical data: 2018 - 2023
Forecast period: 2024 - 2031
Quantitative units: Revenue in USD million and CAGR from 2024 to 2031
Report coverage: Revenue forecast, company ranking, competitive landscape, growth factors, and trends
Ros1 Inhibitor, A Targeted Drug For Non-Small Cell Lung Cancer Market
1.1 SCOPE OF THE REPORT
1.2 MARKET SEGMENT ANALYSIS
1.3 REGULATORY SCENARIO BY REGION/COUNTRY
1.4 MARKET INVESTMENT SCENARIO STRATEGIC
1.5 MARKET ANALYSIS BY TYPE (USD MILLION)
1.6 MARKET ANALYSIS BY APPLICATION (USD MILLION)
2.1 DRIVER, RESTRAINT, CHALLENGE AND OPPORTUNITIES ANALYSIS
2.1.1 MARKET DRIVER ANALYSIS
2.1.2 MARKET RESTRAINT ANALYSIS
2.1.3 MARKET OPPORTUNITY
2.1.4 MARKET CHALLENGES
3.1 INDUSTRY TRENDS
3.1.1 SWOT ANALYSIS
3.1.2 PESTEL ANALYSIS
3.1.3 PORTER’S FIVE FORCES ANALYSIS
3.2 POTENTIAL MARKET AND GROWTH POTENTIAL ANALYSIS
4.1 COVID-19 ANALYSIS
5.1 GLOBAL ROS1 INHIBITOR, A TARGETED DRUG FOR NON-SMALL CELL LUNG CANCER MARKET, SALES AREA, TYPE
5.2 MERGERS & ACQUISITIONS, PARTNERSHIPS, PRODUCT LAUNCH, AND COLLABORATION IN GLOBAL ROS1 INHIBITOR, A TARGETED DRUG FOR NON-SMALL CELL LUNG CANCER MARKET
7.1 GLOBAL ROS1 INHIBITOR, A TARGETED DRUG FOR NON-SMALL CELL LUNG CANCER MARKET SIZE AND SHARE (2018-2031) (USD MILLION)
8.1 GLOBAL ROS1 INHIBITOR, A TARGETED DRUG FOR NON-SMALL CELL LUNG CANCER MARKET SIZE AND SHARE BY TYPE (2018-2023) (USD MILLION)
8.2 GLOBAL ROS1 INHIBITOR, A TARGETED DRUG FOR NON-SMALL CELL LUNG CANCER MARKET SIZE AND SHARE BY TYPE (2024-2031) (USD MILLION)
9.1 GLOBAL ROS1 INHIBITOR, A TARGETED DRUG FOR NON-SMALL CELL LUNG CANCER MARKET SIZE AND SHARE BY APPLICATION (2018-2023) (USD MILLION)
9.2 GLOBAL ROS1 INHIBITOR, A TARGETED DRUG FOR NON-SMALL CELL LUNG CANCER MARKET SIZE AND SHARE BY APPLICATION (2024-2031) (USD MILLION)
10.1 GLOBAL ROS1 INHIBITOR, A TARGETED DRUG FOR NON-SMALL CELL LUNG CANCER MARKET SIZE AND SHARE BY REGION (2018-2023) (USD MILLION)
10.2 GLOBAL ROS1 INHIBITOR, A TARGETED DRUG FOR NON-SMALL CELL LUNG CANCER MARKET SIZE AND SHARE BY REGION (2024-2031) (USD MILLION)
11.1 NORTH AMERICA ROS1 INHIBITOR, A TARGETED DRUG FOR NON-SMALL CELL LUNG CANCER MARKET SIZE AND SHARE BY COUNTRY (2018-2023) (USD MILLION)
11.2 NORTH AMERICA ROS1 INHIBITOR, A TARGETED DRUG FOR NON-SMALL CELL LUNG CANCER MARKET SIZE AND SHARE BY COUNTRY (2024-2031) (USD MILLION)
11.3 NORTH AMERICA ROS1 INHIBITOR, A TARGETED DRUG FOR NON-SMALL CELL LUNG CANCER MARKET SIZE AND SHARE BY TYPE (2018-2023) (USD MILLION)
11.4 NORTH AMERICA ROS1 INHIBITOR, A TARGETED DRUG FOR NON-SMALL CELL LUNG CANCER MARKET SIZE AND SHARE BY TYPE (2024-2031) (USD MILLION)
11.5 NORTH AMERICA ROS1 INHIBITOR, A TARGETED DRUG FOR NON-SMALL CELL LUNG CANCER MARKET SIZE AND SHARE BY APPLICATION (2018-2023) (USD MILLION)
11.6 NORTH AMERICA ROS1 INHIBITOR, A TARGETED DRUG FOR NON-SMALL CELL LUNG CANCER MARKET SIZE AND SHARE BY APPLICATION (2024-2031) (USD MILLION)
12.1 EUROPE ROS1 INHIBITOR, A TARGETED DRUG FOR NON-SMALL CELL LUNG CANCER MARKET SIZE AND SHARE BY COUNTRY (2018-2023) (USD MILLION)
12.2 EUROPE ROS1 INHIBITOR, A TARGETED DRUG FOR NON-SMALL CELL LUNG CANCER MARKET SIZE AND SHARE BY COUNTRY (2024-2031) (USD MILLION)
12.3 EUROPE ROS1 INHIBITOR, A TARGETED DRUG FOR NON-SMALL CELL LUNG CANCER MARKET SIZE AND SHARE BY TYPE (2018-2023) (USD MILLION)
12.4 EUROPE ROS1 INHIBITOR, A TARGETED DRUG FOR NON-SMALL CELL LUNG CANCER MARKET SIZE AND SHARE BY TYPE (2024-2031) (USD MILLION)
12.5 EUROPE ROS1 INHIBITOR, A TARGETED DRUG FOR NON-SMALL CELL LUNG CANCER MARKET SIZE AND SHARE BY APPLICATION (2018-2023) (USD MILLION)
12.6 EUROPE ROS1 INHIBITOR, A TARGETED DRUG FOR NON-SMALL CELL LUNG CANCER MARKET SIZE AND SHARE BY APPLICATION (2024-2031) (USD MILLION)
13.1 ASIA PACIFIC ROS1 INHIBITOR, A TARGETED DRUG FOR NON-SMALL CELL LUNG CANCER MARKET SIZE AND SHARE BY COUNTRY (2018-2023) (USD MILLION)
13.2 ASIA PACIFIC ROS1 INHIBITOR, A TARGETED DRUG FOR NON-SMALL CELL LUNG CANCER MARKET SIZE AND SHARE BY COUNTRY (2024-2031) (USD MILLION)
13.3 ASIA PACIFIC ROS1 INHIBITOR, A TARGETED DRUG FOR NON-SMALL CELL LUNG CANCER MARKET SIZE AND SHARE BY TYPE (2018-2023) (USD MILLION)
13.4 ASIA PACIFIC ROS1 INHIBITOR, A TARGETED DRUG FOR NON-SMALL CELL LUNG CANCER MARKET SIZE AND SHARE BY TYPE (2024-2031) (USD MILLION)
13.5 ASIA PACIFIC ROS1 INHIBITOR, A TARGETED DRUG FOR NON-SMALL CELL LUNG CANCER MARKET SIZE AND SHARE BY APPLICATION (2018-2023) (USD MILLION)
13.6 ASIA PACIFIC ROS1 INHIBITOR, A TARGETED DRUG FOR NON-SMALL CELL LUNG CANCER MARKET SIZE AND SHARE BY APPLICATION (2024-2031) (USD MILLION)
14.1 LATIN AMERICA ROS1 INHIBITOR, A TARGETED DRUG FOR NON-SMALL CELL LUNG CANCER MARKET SIZE AND SHARE BY COUNTRY (2018-2023) (USD MILLION)/p>
14.2 LATIN AMERICA ROS1 INHIBITOR, A TARGETED DRUG FOR NON-SMALL CELL LUNG CANCER MARKET SIZE AND SHARE BY COUNTRY (2024-2031) (USD MILLION)
14.3 LATIN AMERICA ROS1 INHIBITOR, A TARGETED DRUG FOR NON-SMALL CELL LUNG CANCER MARKET SIZE AND SHARE BY TYPE (2018-2023) (USD MILLION)
14.4 LATIN AMERICA ROS1 INHIBITOR, A TARGETED DRUG FOR NON-SMALL CELL LUNG CANCER MARKET SIZE AND SHARE BY TYPE (2024-2031) (USD MILLION)
14.5 LATIN AMERICA ROS1 INHIBITOR, A TARGETED DRUG FOR NON-SMALL CELL LUNG CANCER MARKET SIZE AND SHARE BY APPLICATION (2018-2023) (USD MILLION)
14.6 LATIN AMERICA ROS1 INHIBITOR, A TARGETED DRUG FOR NON-SMALL CELL LUNG CANCER MARKET SIZE AND SHARE BY APPLICATION (2024-2031) (USD MILLION)
15.1 MIDDLE EAST & AFRICA ROS1 INHIBITOR, A TARGETED DRUG FOR NON-SMALL CELL LUNG CANCER MARKET SIZE AND SHARE BY COUNTRY (2018-2023) (USD MILLION)
15.2 MIDDLE EAST & AFRICA ROS1 INHIBITOR, A TARGETED DRUG FOR NON-SMALL CELL LUNG CANCER MARKET SIZE AND SHARE BY COUNTRY (2024-2031) (USD MILLION)
15.3 MIDDLE EAST & AFRICA ROS1 INHIBITOR, A TARGETED DRUG FOR NON-SMALL CELL LUNG CANCER MARKET SIZE AND SHARE BY TYPE (2018-2023) (USD MILLION)
15.4 MIDDLE EAST & AFRICA ROS1 INHIBITOR, A TARGETED DRUG FOR NON-SMALL CELL LUNG CANCER MARKET SIZE AND SHARE BY TYPE (2024-2031) (USD MILLION)
15.5 MIDDLE EAST & AFRICA ROS1 INHIBITOR, A TARGETED DRUG FOR NON-SMALL CELL LUNG CANCER MARKET SIZE AND SHARE BY APPLICATION (2018-2023) (USD MILLION)
15.6 MIDDLE EAST & AFRICA ROS1 INHIBITOR, A TARGETED DRUG FOR NON-SMALL CELL LUNG CANCER MARKET SIZE AND SHARE BY APPLICATION (2024-2031)< (USD MILLION)/p>
16.1 Roche
16.1.1 COMPANY DETAILS
16.1.2 FINANCIALS (USD MILLION)
16.1.3 PRODUCT SUMMARY
16.1.4 RECENT DEVELOPMENTS
16.2 Pfizer
16.3 Beacon Pharma Limited
16.4 Drug International Limted
16.5 Incepta Pharmaceuticals
18.1 METHODOLOGY
18.2 RESEARCH DATA SOURCE
18.2.1 SECONDARY DATA
18.2.2 KEY DATA FROM SECONDARY
18.2.3 PRIMARY DATA
18.2.4 KEY DATA FROM PRIMARY
18.2.5 INDUSTRY INSIGHT FROM PROFESSIONAL LEADERS
18.2.6 MARKET ESTIMATION
18.2.7 MARKET ESTIMATION: TOP-DOWN AND BOTTOM-UP APPROACH
18.2.8 LEGAL DISCLAIMER
Market Segments
By TypeCozotinib
Laratini
Ntrotini
other
By Application
Non small cell lung cancer squamous cell carcinoma
Adenocarcinoma of non-small cell lung cancer
Non small cell lung cancer Large cell carcinoma
Companies
Roche
Pfizer
Beacon Pharma Limited
Drug International Limted
Incepta Pharmaceuticals
BROWSE INDUSTRY
- PROACTIVE
- QUALITY & RELIABILITY
- GLOBAL OUTREACH
- COMPETITIVE PRICING
WHY CHOOSE US
We manage our resources 24/7 to identify issues and address them before they become problems.
We are committed to providing reliable and highly accurate data with an excellent quality control system.
6 Major regions and 40+ countries level analysis accomplished.
Our pricing strategy is highly competitive in the market, without compensating on the quality and the timeline of project delivery.